

# Vladimir Zah

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7835897/publications.pdf>

Version: 2024-02-01

16  
papers

225  
citations

1307594

7  
h-index

1058476

14  
g-index

17  
all docs

17  
docs citations

17  
times ranked

362  
citing authors

#	ARTICLE	IF	CITATIONS
1	A US Retrospective Claims Analysis Comparing Healthcare Costs of Patients Transitioning from Immediate-Release Oxycodone to Two Different Formulations of Extended-Release Oxycodone: Xtampza ER or OxyContin. ClinicoEconomics and Outcomes Research, 2022, Volume 14, 119-128.	1.9	0
2	The burden of productivity loss of U.S. commercially insured patients diagnosed with Dupuytren's disease undergoing collagenase versus fasciectomy treatment. Expert Review of Pharmacoeconomics and Outcomes Research, 2021, 21, 127-136.	1.4	1
3	Healthcare Costs and Resource Use of Patients with Dupuytren Contracture Treated with Collagenase Clostridium Histolyticum or Fasciectomy: A Propensity Matching Analysis. ClinicoEconomics and Outcomes Research, 2020, Volume 12, 635-643.	1.9	7
4	Future of Data Analytics in the Era of the General Data Protection Regulation in Europe. Pharmacoeconomics, 2020, 38, 1021-1029.	3.3	7
5	Concomitant use of benzodiazepines in chronic pain patients adherent to extended-release tapentadol or oxycodone treatment—A retrospective claims analysis. Journal of Opioid Management, 2020, 16, 461-479.	0.5	1
6	Multicriteria Decision Analysis to Support Health Technology Assessment Agencies: Benefits, Limitations, and the Way Forward. Value in Health, 2019, 22, 1283-1288.	0.3	97
7	Healthcare Costs And Resource Utilization In Chronic Pain Patients Treated With Extended-Release Formulations Of Tapentadol, Oxycodone, Or Morphine Stratified By Type Of Pain: A Retrospective Claims Analysis, 2012–2016. Journal of Pain Research, 2019, Volume 12, 3037-3048.	2.0	1
8	How can multi criteria decision analysis support value assessment of pharmaceuticals? - Findings from a systematic literature review. Expert Review of Pharmacoeconomics and Outcomes Research, 2018, 18, 379-391.	1.4	11
9	HEALTH TECHNOLOGY ASSESSMENT IN SERBIA. International Journal of Technology Assessment in Health Care, 2017, 33, 384-389.	0.5	3
10	Economic and health implications from earlier detection of HIV infection in the United Kingdom. HIV/AIDS - Research and Palliative Care, 2016, 8, 67.	0.8	0
11	The use of non-economic criteria in pricing and reimbursement decisions in Central and Eastern Europe: issues, trends and recommendations. Expert Review of Pharmacoeconomics and Outcomes Research, 2016, 16, 483-488.	1.4	3
12	Health Technology Assessment for Molecular Diagnostics: Practices, Challenges, and Recommendations from the Medical Devices and Diagnostics Special Interest Group. Value in Health, 2016, 19, 577-587.	0.3	31
13	Budgetary impact of the utilization of buprenorphine/naloxone sublingual film and tablet for Medicaid in the United States. Journal of Medical Economics, 2015, 18, 600-611.	2.1	11
14	Persistence and healthcare utilization associated with the use of buprenorphine/naloxone film and tablet formulation therapy in adults with opioid dependence. Journal of Medical Economics, 2014, 17, 626-636.	2.1	17
15	Analysis of Buprenorphine/Naloxone Dosing Impact on Treatment Duration, Resource Use and Costs in the Treatment of Opioid-Dependent Adults: A Retrospective Study of US Public and Private Health Care Claims. Postgraduate Medicine, 2014, 126, 113-120.	2.0	19
16	Role of health technology assessment in the process of implementation of the EU Transparency Directive: relevant experience from Central Eastern European countries. Expert Review of Pharmacoeconomics and Outcomes Research, 2012, 12, 283-287.	1.4	16